Defendant

Hetero Drugs Ltd.

2 cases as defendant.

Cases
2
Active
0
2 closed
Filed
2017
Top venue
D. New Jersey
1 case

Celgene Corp. v. Hetero Labs Ltd. et al.

terminated
Docket:
2:17-cv-03387
Filed:
2017-05-11
Terminated:
2021-08-19
Patents:8828427
π Celgene Corp.Δ Hetero Labs Ltd.Δ Hetero Labs Ltd. Unit-VΔ Hetero Drugs Ltd.Δ Hetero USA, Inc.Δ Aurobindo Pharma Ltd.Δ Aurobindo Pharma USA, Inc.Δ Aurolife Pharma LLCΔ Eugia Pharma Specialties Ltd.Δ Apotex Inc.Δ Apotex Corp.Δ Mylan Pharmaceuticals, Inc.Δ Mylan Inc.Δ Mylan N.V.Δ Breckenridge Pharmaceutical, Inc.

Hatch-Waxman ANDA litigation. The '427 was expressly named among the patents-in-suit, but Celgene withdrew its '427 infringement claims. Consolidated/coordinated for claim construction with 17-cv-03159. Case terminated 2021-08-19.

Celgene Corporation v. Hetero Labs Ltd. et al.

settled
Docket:
2:17-cv-03387
Court:
D.N.J.
Patents:873542881582627393939
π Celgene CorporationΔ Hetero Labs Ltd.Δ Hetero Drugs Ltd.Δ Hetero Unit-VΔ Hetero USA

Celgene brought a §271(e)(2) ANDA action against Hetero in D.N.J. regarding the '428 patent. Hetero counterclaimed for declaratory judgment of invalidity/non-infringement of the '428 patent; the court issued a Markman ruling on 'treating multiple myeloma' in the '262, '3,939 and '428 patents, and the case was resolved by settlement.